dPCR LNA Mutation Assays

For detecting specific DNA sequence mutations related to cancer and oncogenesis

  • Duplex assay design detects mutated and wild-type sequences
  • Choice of FAM + HEX or Atto 550 + ROX fluorescent dye combinations
  • LNA-enhanced primers and probes increase assay specificity and sensitivity
  • Wet-lab tested dPCR assays available for more than 200 targets
  • Suitable for use with circulating tumor DNA, liquid biopsy, FFPE and other tissue samples
  • Intended for use with QIAcuity MasterMix

Product

ProductList_Title

ProductList_Teaser_CompareAll_Title

ProductList_Teaser_CompareAll_Description

GeneSymbols
ABL1 (4)
BRAF (9)
BTK (2)
CancerTypes
Acute Leukemias (67)
Breast Cancer (33)
Chronic Leukemia (68)
You've viewed 5 of 201 Products
Loading

Resources_Title

Available Product Catalog (2)
Protocols (3)
Digital PCR (dPCR) is a powerful technique that detects and quantifies ultra-rare mutations in a high background of wild-type cfDNA down to 0.1% variant allele frequency. Here, we describe end-to-end manual and automated workflows that enable accurate detection and absolute quantification of ultra-rare PIK3CA variants in cfDNA using the QIAcuity Digital PCR System.
Application Note: Optimized urine liquid biopsy workflow: From sample collection to cfDNA stabilization and purification, ready for digital PCR analysis
User Manuals (1)
Safety Data Sheets (1)
Download Safety Data Sheets for QIAGEN product components.
Certificates of Analysis (1)